151 related articles for article (PubMed ID: 24719948)
1. Elevated expression of Bmi1 in hepatocellular carcinoma with bile duct tumor thrombi.
Zhang R; Xu LB; Zeng H; Yu XH; Wang J; Liu C
Hepatogastroenterology; 2013; 60(128):2042-7. PubMed ID: 24719948
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus.
Yeh TS; Wang F; Chen TC; Yeh CN; Yu MC; Jan YY; Chen MF
Ann Surg; 2014 Feb; 259(2):346-54. PubMed ID: 24135722
[TBL] [Abstract][Full Text] [Related]
3. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
5. Progenitor gene DLK1 might be an independent prognostic factor of liver cancer.
Jin ZH; Yang RJ; Dong B; Xing BC
Expert Opin Biol Ther; 2008 Apr; 8(4):371-7. PubMed ID: 18352842
[TBL] [Abstract][Full Text] [Related]
6. Pathology of combined hepatocellular-cholangiocarcinoma.
Yeh MM
J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
[TBL] [Abstract][Full Text] [Related]
7. Combined hepatocellular-cholangiocarcinoma. Cytologic findings in four cases.
Dusenbery D
Acta Cytol; 1997; 41(3):903-9. PubMed ID: 9167724
[TBL] [Abstract][Full Text] [Related]
8. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies.
Sasaki M; Yamaguchi J; Ikeda H; Itatsu K; Nakanuma Y
Hum Pathol; 2009 Dec; 40(12):1723-30. PubMed ID: 19695678
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.
Xu LB; Qin YF; Su L; Huang C; Xu Q; Zhang R; Shi XD; Sun R; Chen J; Song Z; Jiang X; Shang L; Xiao G; Kong X; Liu C; Wong PP
Nat Commun; 2023 Nov; 14(1):7033. PubMed ID: 37923799
[TBL] [Abstract][Full Text] [Related]
11. Histopathology of hepatocellular carcinoma.
Schlageter M; Terracciano LM; D'Angelo S; Sorrentino P
World J Gastroenterol; 2014 Nov; 20(43):15955-64. PubMed ID: 25473149
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver.
Tsuneyama K; Kaizaki Y; Doden K; Kidani E; Harada K; Sasaki M; Nakanuma Y
Pathol Int; 2003 Feb; 53(2):90-7. PubMed ID: 12588436
[TBL] [Abstract][Full Text] [Related]
13. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi.
Pang YB; Zhong JH; Luo XL; Ou C; Guo Z; Xiang BD; Peng NF; Li LQ
Tumour Biol; 2016 May; 37(5):5879-84. PubMed ID: 26586401
[TBL] [Abstract][Full Text] [Related]
15. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum.
Morcos M; Dubois S; Bralet MP; Belghiti J; Degott C; Terris B
Am J Clin Pathol; 2001 Nov; 116(5):738-43. PubMed ID: 11710692
[TBL] [Abstract][Full Text] [Related]
16. A combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features.
Papotti M; Sambataro D; Marchesa P; Negro F
Liver; 1997 Feb; 17(1):47-52. PubMed ID: 9062880
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
19. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
[TBL] [Abstract][Full Text] [Related]
20. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
